Treatment of Bulbar Urethral Strictures With Optilume Drug-Coated Balloons in an Untreated Population
Condition(s) studied
Investigational drug(s) / intervention(s)
Optilume DCB: Optilume DCB is a drug-coated balloon catheter designed for the treatment of bulbar urethral strictures. It combines mechanical dilation with localized drug delivery to reduce stricture recurrence and promote urethral healing. The balloon is coated with paclitaxel, an antiproliferative agent, to minimize scar tissue formation and improve treatment outcomes.
Standard Direct Visual Internal Urethrotomy (DVIU): Standard Direct Visual Internal Urethrotomy (DVIU), also known as Sachse Internal Urethrotomy, is a minimally invasive endoscopic procedure for treating urethral strictures.
Study summary
This randomized controlled trial investigates the effectiveness and safety of the Optilume® drug-coated balloon (DCB) compared to standard direct visual internal urethrotomy (DVIU) in the treatment of bulbar urethral strictures. The primary objective is to assess freedom from repeat intervention at 12 months. Secondary objectives include evaluating urethral patency, urinary symptoms, and sexual function through objective measures (Qmax, PVR, cystoscopy) and patient-reported outcomes (USS-PROM, IPSS, IIEF-5). The study will recruit 140 participants across multiple sites, with follow-ups conducted at 6 and 12 months. This trial seeks to provide evidence for Optilume DCB as a safe and effective alternative to standard treatment.
Eligibility
Primary outcome measure(s)
- Freedom from Repeat Intervention at 12 Months — 12 months post-intervention
"The primary outcome is the proportion of participants who remain free from repeat intervention for urethral stricture recurrence at 12 months following treatment. Repeat intervention is defined as any procedure to address stricture recurrence, such as dilation, DVIU, or urethroplasty. Referrals for repeat interventions made within the 12-month follow-up period will also be included, even if the procedure itself is scheduled beyond the 12-month mark."
Trial sites (3)
| Facility | City | Region | Status |
|---|---|---|---|
| Gødstrup Regional Hospital | Gødstrup | Central Jutland | |
| Aalborg University Hospital | Aalborg | Region North Jutland | |
| North Denmark Regional Hospital | Hjørring | Region North Jutland |
More Aalborg University Hospital trials in Denmark
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06827210 on ClinicalTrials.gov ↗ ← All trials in Denmark